MétaCan
Menu
Back to cohort
Record W2727356734 · doi:10.1111/bph.13934

AQX‐1125, small molecule SHIP1 activator inhibits bleomycin‐induced pulmonary fibrosis

2017· article· en· W2727356734 on OpenAlexaff
Jennifer Cross, Grant R. Stenton, Curtis Harwig, Csaba Szabó, Tiziana Genovese, Rosanna Di Paola, Emanuela Esposito, Salvatore Cuzzocrea, Lloyd Mackenzie

Bibliographic record

VenueBritish Journal of Pharmacology · 2017
Typearticle
Languageen
FieldMedicine
TopicInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Canadian institutionsInimex Pharmaceuticals (Canada)
Fundersnot available
KeywordsBleomycinPulmonary fibrosisActivator (genetics)Small moleculeFibrosisChemistryIdiopathic pulmonary fibrosisMedicineCancer researchLungPharmacologyPathologyInternal medicineBiochemistryReceptor

Abstract

fetched live from OpenAlex

Background and Purpose The phosphatase SHIP1 negatively regulates the PI3K pathway, and its predominant expression within cells of the haematopoietic compartment makes SHIP1 activation a novel strategy to limit inflammatory signalling generated through PI3K. AQX‐1125 is the only clinical‐stage, orally administered, SHIP1 activator. Here, we demonstrate the prophylactic and therapeutic effects of AQX‐1125, in a mouse model of bleomycin‐induced lung fibrosis. Experimental Approach For prophylactic evaluation, AQX‐1125 (3, 10 or 30 mg·kg−1·d−1, p.o.) or dexamethasone (1 mg·kg−1·d−1, i.p.) were given to CD‐1 mice starting 3 days before intratracheal administration of bleomycin (0.1 IU per mouse) and continued daily for 7 or 21 days. Therapeutic potentials of AQX‐1125 (3, 10 or 30 mg·kg−1·d−1, p.o.) or pirfenidone (90 mg·kg−1·d−1, p.o.) were assessed by initiating treatment 13 days after bleomycin instillation and continuing until day 28. Key Results Given prophylactically, AQX‐1125 (10 and 30 mg·kg−1) reduced histopathological changes in lungs, 7 and 21 days following bleomycin‐induced injury. At the same doses, AQX‐1125 reduced the number of total leukocytes, neutrophil activity, TGF‐β immunoreactivity and soluble collagen in lungs. Administered therapeutically, AQX‐1125 (10 and 30 mg·kg−1) improved lung histopathology, cellular infiltration and reduced lung collagen content. At 30 mg·kg−1, the effects of AQX‐1125 were similar to those of pirfenidone (90 mg·kg−1) with corresponding improvements in disease severity. Conclusions and Implications AQX‐1125 prevented bleomycin‐induced lung injury during the inflammatory and fibrotic phases. AQX‐1125, given therapeutically, modified disease progression and improved survival, as effectively as pirfenidone.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.024
GPT teacher head0.304
Teacher spread0.279 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations19
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueBritish Journal of PharmacologySame topicInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisFrench-language works237,207